CN106728453B - Pharmaceutical composition for regulating respiratory and nervous systems and application thereof - Google Patents
Pharmaceutical composition for regulating respiratory and nervous systems and application thereof Download PDFInfo
- Publication number
- CN106728453B CN106728453B CN201710052587.4A CN201710052587A CN106728453B CN 106728453 B CN106728453 B CN 106728453B CN 201710052587 A CN201710052587 A CN 201710052587A CN 106728453 B CN106728453 B CN 106728453B
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- rhinitis
- sieving
- regulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Abstract
The invention discloses a pharmaceutical composition for regulating respiratory and nervous systems and application thereof. The pharmaceutical composition for regulating the respiratory system and the nervous system comprises 100-500 parts of rhizoma atractylodis, 50-250 parts of philippine violet herb, 100-500 parts of costustoot, 100-400 parts of folium artemisiae argyi and 20-80 parts of benzoin. The application is the application of the pharmaceutical composition for regulating the respiratory system and the nervous system in preparing the medicines for preventing/treating tracheitis and rhinitis. The invention solves the problems that the medicament for treating tracheitis and rhinitis in the current market generates larger smoke to cause lung discomfort due to unsatisfactory sublimation of medicinal components, the use formula is complicated, the price of the medicament formula material is too high, and the cost performance is too low. When the fumigant for treating tracheitis and rhinitis is used, the common electric heating mosquito-repellent incense box is opened, the mosquito-repellent incense tablet added with the fumigant for treating tracheitis and rhinitis is inserted, and after electricity is inserted, the effective components of the medicine are volatilized into the air through electric heating, so that the fumigant is favorably inhaled when a person falls asleep.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for regulating respiratory and nervous systems and application thereof.
Background
Tracheitis is inflammatory change of the mucous membrane of the trachea and the bronchus caused by infection or non-infection factors, and mucus secretion is increased to influence the secretion function of the alveoli and the ventilation function of the lung. Clinically, the cough, the expectoration or the accompanied asthma is mainly characterized by long-term cough, expectoration or asthma. Rhinitis, an inflammatory disease of the nasal cavity, is inflammation of the mucous membrane of the nasal cavity caused by viruses, bacteria, allergens, various physicochemical factors and certain systemic diseases. The medicine is taken orally or administered intravenously with antibiotics, antivirus, vitamins, etc., or is taken orally with Chinese medicinal decoction, pill, etc., or is administered with Chinese medicinal incense or bathing agent, or more advanced aerosol. But the effect is not ideal enough. Therefore, it is necessary to develop a product capable of solving the above problems.
Disclosure of Invention
A first object of the present invention is to provide a pharmaceutical composition for regulating the respiratory and nervous systems; the second purpose is to provide the application of the pharmaceutical composition for regulating the respiratory and nervous systems.
The first purpose of the invention is realized in such a way that the pharmaceutical composition for regulating the respiratory and nervous systems comprises 100-500 parts of rhizoma atractylodis, 50-250 parts of herba violae, 100-500 parts of elecampane, 100-400 parts of folium artemisiae argyi and 20-80 parts of benzoin.
The second purpose of the invention is realized by the application of the pharmaceutical composition for regulating the respiratory and nervous systems in the preparation of medicines for preventing/treating tracheitis and rhinitis.
The invention solves the problems that the medicament for treating tracheitis and rhinitis in the current market has poor sublimation property of medicinal components, generates larger smoke to cause lung discomfort, has complicated ancient languages, and has expensive medicinal composition materials and poor cost performance. When the fumigant for treating tracheitis and rhinitis is used, the common electric heating mosquito-repellent incense box is opened, the mosquito-repellent incense tablet added with the fumigant for treating tracheitis and rhinitis is inserted, and after electricity is inserted, the effective components of the medicine are volatilized into the air through electric heating, so that the fumigant is favorably inhaled when a person falls asleep.
The fumigant of the invention has the following advantages:
firstly, it is different from the traditional fumigant and the direct nasal feeding administration, such as snuff.
Secondly, all respiratory diseases originate from the lung and aggravate in the lung, so the medicine components directly reach the focus by adopting an inhalation administration mode, and the medicine has the characteristic of targeted administration.
Thirdly, the mosquito-repellent incense is used in the form of an electric heating mosquito-repellent incense tablet, the administration time is long, the administration is convenient, the administration dosage is small, no large toxic or side effect is generated, and the side effect of inhaling the medicine into the lung, such as lung obstructive disease, is avoided.
Fourth, the administration form has certain advantages than the existing more advanced atomization agent, such as chemical preparation has certain toxic and side effects, the using equipment is complicated, the cross contamination after the equipment is used alternately after the dressing change, and the using cost is high.
Detailed Description
The present invention is further illustrated by the following examples, which are not intended to be limiting in any way, and any modifications or alterations based on the teachings of the present invention are intended to fall within the scope of the present invention.
The pharmaceutical composition for regulating the respiratory system and the nervous system comprises 100-500 parts of rhizoma atractylodis, 50-250 parts of herba violae, 100-500 parts of radix aucklandiae, 100-400 parts of folium artemisiae argyi and 20-80 parts of benzoin.
The pharmaceutical composition for regulating the respiratory system and the nervous system comprises 200-400 parts of rhizoma atractylodis, 100-200 parts of philippine violet herb, 200-400 parts of costustoot, 200-300 parts of folium artemisiae argyi and 40-60 parts of benzoin.
The pharmaceutical composition for regulating the respiratory system and the nervous system comprises 250-350 parts of rhizoma atractylodis, 120-180 parts of philippine violet herb, 250-350 parts of costustoot, 220-280 parts of folium artemisiae argyi and 45-55 parts of benzoin.
The application of the pharmaceutical composition for regulating the respiratory system and the nervous system is characterized in that the pharmaceutical composition for regulating the respiratory system and the nervous system is applied to the preparation of medicines for preventing/treating tracheitis and rhinitis.
The medicament for treating tracheitis and rhinitis is a fumigant for treating tracheitis and rhinitis.
The fumigant of the medicine for treating tracheitis and rhinitis is prepared by the following steps:
A. pretreatment:
1) crushing and sieving the raw materials of rhizoma atractylodis and elecampane according to the formula ratio to obtain a material a, and adding the material a with the volume percentage concentration of 8-10 times of the weight of the material aPurifying the water solution, standing for 2-3 hours, extracting at 80-100 ℃ for 30-50 min, collecting volatile condensate, standing to remove water in the volatile, and adding anhydrous Na2SO4Mixing, dehydrating, and filtering to obtain volatile oil b (method 1).
Placing the extract a in a closed container, adding petroleum ether with the weight of 3-5 times of the extract a, performing ultrasonic extraction (power of 140-300W and frequency of 3000-15000 Hz) for 2-3 times, combining the extract, performing suction filtration, and recovering (evaporating) the petroleum ether to obtain volatile oil b (method 2).
Placing a in a Soxhlet extractor, extracting with petroleum ether as solvent until the extractive solution is nearly colorless, and recovering (evaporating) petroleum ether to obtain volatile oil b (method 3).
Taking a and placing CO2In an extraction kettle, the extraction conditions are that the extraction temperature is 45 ℃ under the pressure of 20 MPa, and CO is added2The flow rate is 3L/h, the temperature of the separation kettle is 45 ℃, and the extraction time is 3h, and the extract is collected to obtain the volatile oil b (method 4).
2) Mixing, crushing and sieving the Chinese violet, the folium artemisiae argyi and the benzoin according to the formula ratio to obtain a material c for later use;
B. preparation: and (3) taking the material c as a matrix, adding the volatile oil b, and uniformly mixing to obtain the fumigant of the target medicament for treating tracheitis and rhinitis.
The crushing and sieving in the step 1) is crushing and sieving by a 10-mesh sieve.
The power of ultrasonic extraction in the step 1) is 140W-300W, and the frequency is 3000-15000 Hz.
The crushing and sieving in the step A2) is crushing and sieving by a 100-mesh sieve.
The invention is further illustrated by the following specific examples:
example 1
The volatile oil b1 is prepared from the following raw materials in parts by weight: 50g of rhizoma atractylodis and 50g of costustoot, and the volatile oil b1 can be obtained by the first method to the fourth method. Mixing folium Artemisiae Argyi 50g, herba Violae 50g, and Benzonum 10g, and pulverizing to obtain c 1. Mixing b1 and c1, placing into a container of sublimate, and electrically heating to sublimate the medicine.
Example 2
The volatile oil b2 is prepared from the following raw materials in parts by weight: 100g of rhizoma atractylodis and 20g of costustoot, and the volatile oil b2 can be obtained by the first method to the fourth method. Mixing folium Artemisiae Argyi 60g, herba Violae 30g, and Benzonum 20g, and pulverizing to obtain c 2. Mixing b2 and c2, placing into a container of sublimate, and electrically heating to sublimate the medicine.
Example 3
The volatile oil b3 is prepared from the following raw materials in parts by weight: 20g of rhizoma atractylodis and 100g of costustoot, and volatile oil b3 can be obtained by the first method to the fourth method. Mixing folium Artemisiae Argyi 40g, herba Violae 80g, and Benzonum 40g, and pulverizing to obtain c 3. Mixing b3 and c3, placing into a container of sublimate, and sublimating the sublimate by electric heating (at a temperature lower than 70 ℃).
Example 4
The test was carried out with the pharmaceutical composition for modulating the respiratory and nervous system prepared in example 3:
1. a test method;
90 BALB/c mice were divided into six groups of fifteen mice each, of which the first, second and third groups were administered with 100. mu.g egg protein (VOA) for 1, 7 and 14 days for intraperitoneal sensitization, and the fourth, fifth and sixth groups were administered with 100. mu.g egg white albumin (VOV) and 2mgCa (OH) for 1, 7 and 14 days20.3 ml of suspension is used for nasal drop sensitization.
On the fifteenth day, six groups of mice were placed in a plastic box, 4 ten thousand units of gentamicin, which was inhaled as a nebulized drug, were administered to the second and fifth groups, which were nebulized for 20min/d, with 15g each time 3 hours a day using the respiratory and nervous system-regulating pharmaceutical composition prepared in example 3, for 10 consecutive days.
On the twenty-sixth day, 5 mice were kept alive, and after sacrifice, the lungs were used to observe the result one. The lung weights were averaged and compared.
2. And (3) test results:
example 5
The method of the experiment performed by the pharmaceutical compositions for regulating respiratory system and nervous system prepared in example 1 and example 2 is the same as example 4, and the results show that the pharmaceutical composition for regulating respiratory system and nervous system of the present invention has better curative effect on tracheitis and rhinitis.
Claims (8)
1. A pharmaceutical composition for regulating respiratory and nervous systems is characterized by being prepared from 100-500 parts of rhizoma atractylodis, 50-250 parts of herba violae, 100-500 parts of radix aucklandiae, 100-400 parts of folium artemisiae argyi and 20-80 parts of benzoin, and specifically comprises the following steps:
A. pretreatment:
1) crushing and sieving raw materials including rhizoma atractylodis and elecampane according to a formula ratio to obtain a material a, adding purified water liquid with volume percentage concentration 8-10 times of the weight of the material a, standing for 2-3 hours, extracting at 80-100 ℃ for 30-50 min, collecting volatile condensate in the process, standing to remove water in volatile matters, and adding anhydrous Na2SO4Mixing, dehydrating, and filtering to obtain volatile oil b; or
Placing the extract a in a closed container, adding petroleum ether with the weight of 3-5 times of the extract a, performing ultrasonic extraction for 2-3 times, combining the extract, performing suction filtration, and performing evaporation and recovery on the petroleum ether to obtain volatile oil b; or
Weighing a, placing the a in a Soxhlet extractor, extracting by taking petroleum ether as a solvent until an extracting solution is nearly colorless, and evaporating and recovering the petroleum ether to obtain volatile oil b; or
Taking a and placing CO2In an extraction kettle, the extraction conditions are that the extraction temperature is 45 ℃ under the pressure of 20 MPa, and CO is added2The flow is 3L/h, the temperature of the separation kettle is 45 ℃, and the extraction time is 3h, and the extract is collected to obtain volatile oil b;
2) mixing, crushing and sieving the Chinese violet, the folium artemisiae argyi and the benzoin according to the formula ratio to obtain a material c for later use;
B. preparation: and (4) adding the volatile oil b into the material c serving as a matrix and uniformly mixing to obtain the target pharmaceutical composition.
2. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is prepared from 200-400 parts of rhizoma atractylodis, 100-200 parts of herba violae, 200-400 parts of radix aucklandiae, 200-300 parts of folium artemisiae argyi and 40-60 parts of benzoin.
3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is prepared from 250-350 parts of rhizoma atractylodis, 120-180 parts of herba violae, 250-350 parts of radix aucklandiae, 220-280 parts of folium artemisiae argyi and 45-55 parts of benzoin.
4. The pharmaceutical composition of claim 1, wherein said pulverizing and sieving in step a) is pulverizing and sieving with a 10 mesh sieve.
5. The pharmaceutical composition according to claim 1, wherein the power of the ultrasonic extraction in step A1) is 140W-300W, and the frequency is 3000-15000 Hz.
6. The pharmaceutical composition of claim 1, wherein said pulverizing and sieving in step a 2) is pulverizing and sieving with a 100 mesh sieve.
7. The use of the pharmaceutical composition according to any one of claims 1 to 3, characterized in that the pharmaceutical composition is used for preparing a medicament for preventing or treating tracheitis and rhinitis.
8. The use according to claim 7, wherein the medicament for treating tracheitis and rhinitis is a fumigant for the medicament for treating tracheitis and rhinitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710052587.4A CN106728453B (en) | 2017-01-24 | 2017-01-24 | Pharmaceutical composition for regulating respiratory and nervous systems and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710052587.4A CN106728453B (en) | 2017-01-24 | 2017-01-24 | Pharmaceutical composition for regulating respiratory and nervous systems and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106728453A CN106728453A (en) | 2017-05-31 |
| CN106728453B true CN106728453B (en) | 2021-02-02 |
Family
ID=58942496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710052587.4A Active CN106728453B (en) | 2017-01-24 | 2017-01-24 | Pharmaceutical composition for regulating respiratory and nervous systems and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106728453B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497144A (en) * | 2016-01-22 | 2016-04-20 | 冯悠慈 | Traditional Chinese medicine composition and application of traditional Chinese medicine composition in preparation of medicine for treating rhinitis |
-
2017
- 2017-01-24 CN CN201710052587.4A patent/CN106728453B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497144A (en) * | 2016-01-22 | 2016-04-20 | 冯悠慈 | Traditional Chinese medicine composition and application of traditional Chinese medicine composition in preparation of medicine for treating rhinitis |
Non-Patent Citations (1)
| Title |
|---|
| 气味轻松治疗鼻炎 鼻炎也能"闻"好;兵兵;《http://online.xywy.com/biyan/bydzl/87822.html》;20141031;第1页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106728453A (en) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107789340B (en) | Solution preparation for andrographis paniculata aerosol inhalation and preparation method thereof | |
| CN102961439B (en) | Total flavone extract of Hyssopus officinalis, preparation method thereof and application thereof | |
| CN103585540B (en) | Incense-fumigating oil of rhizoma atractylodis and folium artemisiae argyi | |
| CN111544556A (en) | A Chinese medicinal composition for treating viral common cold and viral pneumonia, and its administration method and preparation method | |
| CN102335274B (en) | Chinese medicinal composition for preventing and treating inflammation-related diseases | |
| CN106728453B (en) | Pharmaceutical composition for regulating respiratory and nervous systems and application thereof | |
| CN101716300B (en) | Cough relief traditional Chinese medicine compound preparation and preparation method thereof | |
| CN106420919A (en) | Preparation method and application of Nepeta bracteatatotal flavonoids | |
| CN113368208A (en) | Antiviral aerosol inhalation solution preparation and preparation method thereof | |
| CN113577173A (en) | Electronic atomized liquid for treating pharyngeal diseases caused by smoking and preparation method thereof | |
| CN104524273A (en) | Preparation method of Yinqiao preparation | |
| CN101502617B (en) | Chinese medicinal composition with cough-suppressing phlegm-dispelling functions and preparation method thereof | |
| CN111617134A (en) | Patchouli oil soft capsule for treating acute upper respiratory tract infection and therapy thereof | |
| CN107243024B (en) | A kind of double golden pharmaceutical compositions connected, a kind of Neulized inhalation solution of double gold even and its preparation method and application | |
| CN112999204A (en) | Shuanghuanglian aerosol inhalation solution preparation and preparation method thereof | |
| CN111514246A (en) | Traditional Chinese medicine composition and mask for preventing novel coronavirus pneumonia | |
| CN113209056A (en) | Trollius chinensis solution preparation for aerosol inhalation and preparation method thereof | |
| CN108992580A (en) | Chinese medicine composition and preparation method thereof for preventing phlegm from forming and stopping coughing | |
| CN115212247B (en) | Preparation of nitraria tangutorum bobr and application thereof | |
| CN103784712A (en) | Health care product capable of repairing lung injuries caused by environmental pollution and preparation method of health care product | |
| CN103623203B (en) | A kind of preparation method of dimethoxanate oral formulations | |
| CN107669890B (en) | A kind of Chinese medicine composition and preparation method thereof with clearing preventing phlegm from forming and stopping coughing effect | |
| CN113827636B (en) | Lung-clearing mixture containing Tibetan four ingredients and application thereof in preparation of medicines for treating respiratory system diseases | |
| CN109966324A (en) | A kind of ginkgo biloba p.e Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN109200120B (en) | Medicine for treating spleen-kidney yang deficiency chronic cough and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Nie Qihua Inventor after: Zhang Zhiqin Inventor after: Yao Ronglin Inventor after: Zhang Helan Inventor after: Yin Minhui Inventor before: Nie Qihua |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |